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Although the formation of -amyloid (A) deposits in the
brain is a hallmark of Alzheimer disease (AD), the soluble olig-
omers rather than the mature amyloid fibrils most likely con-
tribute to A toxicity and neurodegeneration. Thus, the discov-
ery of agents targeting soluble A oligomers is highly desirable
for early diagnosis prior to the manifestation of a clinical AD
phenotype and also more effective therapies. We have previ-
ously reported that a novel 15-amino acid peptide (15-mer), iso-
lated via phage display screening, targeted A and attenuated its
neurotoxicity (Taddei, K., Laws, S. M., Verdile, G., Munns, S.,
D’Costa, K., Harvey, A. R., Martins, I. J., Hill, F., Levy, E., Shaw,
J. E., and Martins, R. N. (2010) Neurobiol. Aging 31, 203–214).
The aim of the current study was to generate and biochemically
characterize analogues of this peptide with improved stability
and therapeutic potential. We demonstrated that a stable ana-
logue of the 15-amino acid peptide (15M S.A.) retained the
activity and potency of the parent peptide and demonstrated
improved proteolytic resistance in vitro (stable to t  300 min,
c.f. t  30 min for the parent peptide). This candidate reduced
the formation of soluble A42 oligomers, with the concurrent
generation of non-toxic, insoluble aggregates measuring up to
25–30 nm diameter as determined by atomic force microscopy.
The 15M S.A. candidate directly interacted with oligomeric
A42, as shown by coimmunoprecipitation and surface plas-
mon resonance/Biacore analysis, with an affinity in the low
micromolar range. Furthermore, this peptide bound fibrillar
A42 and also stained plaques ex vivo in brain tissue from AD
model mice. Given its multifaceted ability to target monomeric
and aggregated A42 species, this candidate holds promise for
novel preclinical AD imaging and therapeutic strategies.
Alzheimer disease (AD)4 is a progressive neurodegenerative
disorder, accounting for 50 –70% of late-onset dementia cases
(2). The major biochemical hallmarks of AD are extracellular
amyloid plaques and intracellular neurofibrillary tangles. The
predominant species present in amyloid plaques is -amyloid
(A), a 4.5-kDa peptide generated through amyloidogenic pro-
cessing (sequential cleavage by - and -secretases) of the par-
ent amyloid precursor protein (APP). This produces two forms
of A, comprising either 40 or 42 amino acids, where the rela-
tive amount of the longer 42-amino acid form (A42) is espe-
cially critical for AD progression, given its higher propensity to
aggregate and form neurotoxic species (3, 4).
In AD brain, the monomeric A42 peptide is known to
aggregate and form various ordered assemblies, which precede
plaque formation. These include low-n oligomers (dimers to
octamers, reviewed in Ref. 5), high molecular weight oligomers
such as A-derived diffusible ligands (6) and globulomers (7),
protofibrils (8), and fibrils (9). Much evidence has indicated that
soluble A42 oligomers, rather than mature amyloid plaques,
correlate with disease severity (10, 11) and contribute to synap-
tic degeneration and neurotoxicity (12, 13). In particular, recent
work has highlighted a role for dimers, trimers, and dodecamer
forms of A oligomers in neuronal dysfunction (see Refs. 14
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The accumulation of A is thought to occur early in the
disease process. Studies in transgenic mice show that cognitive
deficits are associated with small A oligomeric assemblies (16,
17), which precede amyloid deposition and promote Tau phos-
phorylation and tangle formation (18, 19). Further evidence for
a pivotal role for A oligomers in the neurodegenerative pro-
cess is provided by the development of transgenic mice express-
ing oligomers, which show synaptic degeneration, Tau phos-
phorylation, and neuronal loss in the absence of plaques (20).
Although these findings suggest interventions targeting A
oligomers have the potential to halt disease progression, oligo-
mers have proved to be difficult therapeutic targets. This is
partly due to the complex inter-conversion between different
A42 assemblies and the fact that A42 oligomers of different
structure, stability, and concentration may all be neurotoxic
(reviewed in Ref. 21).
We have previously reported a novel 15-amino acid peptide
isolated by subtractive phage display screening, which bound
the toxic human A42 peptide, but not the related, non-toxic
rat A42 peptide. This peptide was shown to target A42 and
attenuate its neurotoxicity (1). In an effort to generate a novel,
specific and stable candidate peptide capable of targeting A42
oligomers, we have exploited the known ability of this peptide
to target A42 and aimed to increase its utility using two
approaches: (i) reduced length for improved permeability
across the blood-brain barrier and peptidomimetic design; and
(ii) increased proteolytic resistance. The stability of these ana-
logues was assessed in vitro and their A42 binding and activity
was assessed biochemically. We have further provided proof-
of-principle experiments to demonstrate that the lead candi-
date peptide shows potential as a preclinical AD imaging agent,
given its ability to bind A42 oligomers in vitro, amyloid
plaques ex vivo, and its potential for transport across the blood-
brain barrier in vivo.
Experimental Procedures
Peptides—Human synthetic A42 peptide was purchased
from the W.M. Keck Foundation Biotechnology Resource Lab-
oratory (Yale University, New Haven, CT). All other unlabeled
peptides used in this study (15-amino acid peptide (15-mer);
(Ac-TNPNRRNRTPQMLKR-NH2  “L-ANA-1” (1)), 15M
S.A. (stable retro-inverso analogue of 15-amino acid peptide;
Ac-rklmqptrnrrnpnt-NH2),5 9 amino acid peptide (9-mer) (15-
mer fragment based on in silico modeling; Ac-NRTPQMLKR-
NH2  L-ANA5),5 9M S.A (stable analogue of the 9-mer; Ac-
rklmqptrn-NH2),5 CTL1 (scrambled control based on 9-mer,
Ac-RNPKMQRTL-NH2), CTL1 S.A. (stable analogue of CTL1,
Ac-ltrqmkpnr-NH2), CTL2 S.A. (retro-inverso stable analogue
control based on unrelated APP 9-amino acid peptide fragment
as reported in Ref. 1; Ac-tlGsGprtt-NH2) were obtained from
Mimotopes, (Melbourne, Australia). Tetramethyl rhodamine
(TMR)-labeled 15M S.A. and CTL2 S.A. were also obtained
from Mimotopes (Melbourne, Australia). Tritium labeling of
15M S.A. peptide was performed by American Radiolabeled
Chemicals, Inc. (St. Louis, MO).
Preparation of A42 Monomers, Oligomers, and Fibrils—
A42 assemblies were prepared as preciously described (22).
Briefly, A42 was solubilized in 1,1,1,3,3,3-hexafluoro-2-pro-
panol (Sigma), dried, and reconstituted in dry dimethyl sulfox-
ide (Sigma) to 5 mM concentration. For monomeric A42, the 5
mM stock was diluted to 100 M in ice-cold Milli-Q water and
used immediately. For oligomeric and fibrillar A42, the 5 mM
stock was diluted to 100 M in either ice-cold Ham’s F-12 media
(C-72110, PromoCell GmbH, Germany) or 10 mM HCl, respec-
tively, and incubated for 24 h at either 4 or 37 °C, respectively.
In Vitro Assay of Peptide Stability—Peptides were prepared
as either 1 or 4 mM solution in PBS. 20 l of the peptide solution
was diluted in either 10% rat brain homogenate (in PBS  0.5%
Triton X-100) or 100% serum. The solution was incubated at
37 °C for different times, and the reaction was stopped by add-
ing cOmplete protease inhibitor mixture (Roche Molecular
Biochemicals, Mannheim, Germany). For 9-mer and 9M S.A.,
the bulk of the brain proteins (but not the peptides) were pre-
cipitated in cold methanol (1:4 (v/v) mixture/methanol) for 1 h
at 20 °C. The precipitated proteins were pelleted by centrifu-
gation (10,000  g, 10 min, 4 °C). The supernatant containing
the peptide was concentrated five times under vacuum and sep-
arated by reversed-phase HPLC (RP-HPLC). Due to recovery
issues with the longer 15-mer and 15M S.A. peptides, samples
were instead lyophilized, extracted in TFA, centrifuged to
remove insoluble material, and separated by RP-HPLC. The
area of the peak (UV absorbance at 205 nm) corresponding to
the intact peptide was measured and compared with an equiv-
alent sample incubated in PBS.
Thioflavin T Assays—This method was adapted from Ref. 23.
Briefly, A42 oligomers were centrifuged (18,000  g, 4 °C, 1
min) to pellet insoluble material. The clarified supernatant (4.5
g/10 l of 100 M stock) was added to a black-walled, clear
bottom 96-well microplate (PerkinElmer Life Sciences) in trip-
licate. 200 l of thioflavin T (ThT) (5 M in 50 mM glycine
NaOH, pH 8.5, 0.22 M filtered) was added and the plates were
read at 3–5 min post-addition in a FLUOSTAR OPTIMA
instrument (excitation filter: 450 nm; emission filter: 490 nm;
30 s mix before reading; gain-adjust to highest reading). Sam-
ples were assayed in triplicate and the blank ThT fluorescence
was subtracted from all readings. Candidate peptides were also
assayed in the absence of A42 for interference in the assay.
Cell Culture, Treatment, and Neurotoxicity Assay—M17
neuroblastoma cells were cultured similar to Ref. 1. Briefly,
M17 cells were seeded in a 48-well plate (25,000 cells/well in
500 l of 1:1 DMEM/Nutrient Mixture F12 (DMEM/F-12) (Life
Technologies)  10% fetal calf serum) overnight. 100 M A42
oligomer stocks ( candidate peptides) were diluted to 20 M
concentration in treatment medium (20% (v/v) Ham’s F-12,
80% (v/v) DMEM (no phenol red)) and used to treat cells (50 –
60% confluence) for 4 days (37 °C, 5% CO2). On the fourth day,
the evaluation of neurotoxicity was performed by measuring
release of lactate dehydrogenase (LDH) (CytoTox-ONETM
Homogeneous Membrane Integrity Assay, Promega) and cell
viability (CellTiter96 Aqueous One Solution Cell Proliferation
Assay (MTS), Promega), according to the manufacturer’s rec-
ommendations. Samples were assayed in triplicate.5 IP Australia provisional patent application number 2013904077.
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SDS-PAGE and Western Immunoblotting—Samples for gel
analysis were prepared in two ways, i.e. denaturing and nonde-
naturing conditions. Non-denatured samples were separated
by electrophoresis using a modified Blue Native-PAGE proto-
col, as described in Ref. 24. Samples were diluted in MOPS
loading buffer (50 mM MOPS, 50 mM Tris, 20% glycerol, 0.05%
Coomassie, pH 7.7) without reducing agent and were not heat
denatured prior to PAGE separation. Where insoluble material
was present in the samples, denaturing conditions were
employed to solubilize this material. In the denaturing condi-
tions, samples were diluted in LDS sample buffer plus reducing
agent (NuPAGE), and heat denatured (72 °C, 10 min) prior to
separation of proteins by SDS-PAGE using NuPAGE Novex
4 –12% BisTris gradient gels and MES SDS running buffer (Life
Technologies). Samples were transferred onto either nitrocel-
lulose (denatured samples) or PVDF (non-denatured samples)
membranes using the iBlot blotting system (Life Technolo-
gies). Samples were subjected to Western immunoblotting with
WO2 antibody (25) (kindly provided by Prof. Colin Masters,
University of Melbourne, Australia), to detect A species.
Bands were visualized using enhanced chemiluminescence
(Amersham Biosciences ECL) and exposure to Hyperfilm ECL
films (GE Healthcare). Films were scanned on a Bio-Rad
GS-800 densitometer and densitometry was conducted with
Bio-Rad Quantity One software.
Atomic Force Microscopy (AFM)—Samples for AFM were
prepared and analyzed according to Ref. 22. Briefly, A samples
were spotted on freshly cleaved grade V1 muscovite mica and
incubated for 5 min. Samples were then rinsed with 0.22-m
syringe-filtered double-distilled water and blow dried with sev-
eral gentle pulses of compressed air (N2). Samples were then
visualized under the AFM (NT-MDT) using semi-contact
mode with the following parameters: a minimum contact force,
amplitude between 0.5 and 2 V (depending on the cantilever) to
generate magnitude 20 nA, and scan rates 0.5–1 Hz. All
data were processed using Nova NT-MDT Software version
1.1.0.1780.
Surface Plasmon Resonance/Biacore Assays—These experi-
ments were performed using a Biacore 3000 Instrument (GE
Healthcare) with a protocol modified from Ref. 26. Either 15M
S.A. peptide, or A42 monomer/aggregates, were immobilized
on separate CM5 sensorchips (GE Healthcare). The 15M S.A.
peptide was immobilized on a CM5 sensorchip via amine cou-
pling, according to the manufacturer’s instructions, to a level of
245 resonance units (RU) (1 RU  1 pg of protein/mm2). Mono-
meric, oligomeric, and fibrillar A42 preparations were immo-
bilized on another CM5 sensorchip (10 M in 10 mM sodium
acetate buffer (pH 4.0), injection for 5 min at a flow rate of 30
l/min) to final levels of 9,084, 11,467, and 4,924 RU, respec-
tively. Note that the oligomeric A42 and fibrillar A42 prep-
arations were prepared 24 h prior to immobilization, whereas
the monomeric A42 was prepared immediately prior to
immobilization to minimize its aggregation. For both sensor-
chips, a reference surface was prepared in parallel (with no
addition of peptide), and used for subtraction of nonspecific
binding. Sensorgrams were obtained using standard conditions
of 30 l/min flow rate and HBS-EP running buffer (0.01 M
HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% (v/v) surfac-
tant P20 (GE Healthcare)) as outlined under “Results.”
Coimmunoprecipitation Analysis—Alexa 488-labeled oA42
was prepared as described in Ref. 27 and incubated with TMR-
labeled 15M S.A. peptide in 300-l reactions in TBS  0.05%
Tween 20 (TBST) with gentle rotation for 16 h at 4 °C. Com-
plexes were captured using 1 g of 6E10 antibody (Covance) for
A (2 h, 4 °C) and then -bind-Sepharose/Protein G-Mag-Sep-
harose (GE Healthcare) (2 h, 4 °C). Following removal of the
supernatant, the beads were washed (3  500 l of TBST) and
samples were separated by denaturing SDS-PAGE on 4 –12%
BisTris NuPAGE gels (Life Technologies). Fluorescently
labeled peptides were visualized by in gel fluorescence using a
Typhoon FLA 9500 imaging system (GE Healthcare).
Immunohistochemistry—Brains were obtained from 8-month-
old 5xFAD or TgCRND8 AD model mice (28) or age-matched
non-transgenic controls and post-fixed and embedded in the
freezing medium as described in Ref. 29. Serial sagittal cryo-
sections were cut at a thickness of 10 m. Positive control
staining for amyloid plaques was performed using thioflavin
S (Thio S) as described in Ref. 30. After the removal of the
freezing medium by serial changes of TBS (pH 7.4), the slide
was incubated for 1 h at room temperature in blocking buffer
(10% goat serum in TBS). The slides were then stained with 1
M TMR-labeled 15M S.A. peptide in 2% goat serum/PBS for
2 h at room temperature. Excess unbound peptide was removed
prior to mounting by extensive washing with TBS. The cover-
slip was mounted using Prolong Gold mounting media (Life
Technologies).
Brain Uptake of 3H-Labeled 15M S.A. following Intravenous
Administration—Animal experiments were approved by the
Monash Institute of Pharmaceutical Sciences Animal Ethics
Committee and were performed in accordance with the Aus-
tralian National Health and Medical Research Council
(NHMRC) guidelines for the care and use of animals for scien-
tific purposes. Male Swiss Outbred mice (6 – 8 weeks of age;
25–30 g) were used in the studies and had free access to food
and water during the experimental periods. An aliquot (50 l)
containing 10 Ci of 3H-labeled 15M S.A. peptide was admin-
istered to mice by tail vein (intravenous) injection. Brain and
plasma samples were collected over a 0.5– 4-h period and the
concentration of 15M S.A. peptide in plasma and brain homo-
genate was performed by liquid scintillation counting (Tri-
Carb 2800 TR; PerkinElmer Life Sciences). The brain concen-
trations were corrected by subtracting the brain microvascular
volume (0.035 ml/g) using [14C]sucrose as a vascular marker
(31). As described previously (32), the brain to plasma ratio of
3H-labeled 15M S.A. peptide was determined using the follow-
ing formula: (corrected number of disintegrations per minute
(dpm) per g of brain tissue)/(number of dpm per ml of plasma).
The intactness of 3H-15M S.A. at post-dose time points follow-
ing intravenous administration was assessed by HPLC. Briefly,
brain samples were homogenized in a volume of MilliQ water
(in ml) equal to twice the weight (in g) of the tissue using a glass
rod. To 300 l of brain homogenate or 100 l of plasma, the
same volume of acetonitrile was added prior to centrifugation
at 14,100  g for 5 min. An aliquot (100 l) of the supernatant
was then loaded onto a Waters Symmetry C18 column (5  4.6
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mm). Mobile phase A consisted of 0.1% (v/v) TFA in MilliQ
water and mobile phase B consisted of 60% (v/v) acetonitrile in
0.1% (v/v) TFA in MilliQ water. 3H-15M S.A. peptide was ana-
lyzed using the following gradient profile: 0 min, 95% A; 0 –10
min, 70% A; 10 –12 min, 95% A. The eluant from the column
was collected every 0.5 min and the dpm of each fraction was
measured by liquid scintillation counting. The profiles (dpm
versus time) of brain and plasma samples were then generated
and compared with those of 3H-15M S.A. peptide solution as
control.
Results
In Vitro Stability of Analogue Peptides with Increased Thera-
peutic Potential—To increase the membrane permeability and
potential for peptidomimetic mimicry, we used in silico mod-
eling to reduce the size of the parent 15-mer to a 9-mer. In
addition, we employed modifications to both the parent 15-mer
and the 9-mer to increase their resistance to proteolytic degra-
dation, generating candidates denoted as 15M S.A. and 9M
S.A.,5 respectively. The in vitro stability of these peptides was
measured following incubation in dilute rat brain homogenate
or serum and HPLC quantification. For brain homogenate, we
found that trace amounts of unmodified 15-mer and none of
the unmodified 9-mer were present at t  30 min (Table 1). In
contrast, the concentrations of both stable analogue peptides
remained relatively unchanged following an extended incuba-
tion of 300 min (Table 1). Similar findings were observed in
100% serum, where compared with unmodified peptide con-
centrations the stable analogues remained relatively unchanged
across the incubation time points (Table 1). These results indi-
cate that modifications to the 9-mer and 15-mer peptides
reduced degradation and thus improved stability. These stable
analogues were investigated further to determine whether they
retained the activity of the parent peptides.
Effects on A42 Aggregation and Neurotoxicity—Given the
neurotoxicity attributed to oligomeric A42, we next assessed
the ability of the stable analogues to influence their formation
and toxicity. We incubated monomeric A42 peptide under
conditions specifically favoring oligomerization for 24 h (22), in
the presence or absence of the candidate peptides. We then
assayed the A42 aggregation in these samples using ThT fluo-
rescence assays and Blue Native-PAGE/Western blotting. We
additionally diluted samples to 20 M A42 concentration,
treated M17 neuroblastoma cells, and quantified neurotoxicity
following 4 days of treatment. ThT analysis revealed that both
the parent 15-mer and 15M S.A. peptide reduced ThT fluores-
cence (and thus A42 aggregation and oligomerization) in a
dose-dependent manner and with similar potency (Fig. 1A). In
comparison, the 9-mer peptide showed similar activity, but
reduced potency, and the 9M S.A. peptide showed overlapping
activity with a scrambled control peptide (CTL1) (Fig. 1A). Sim-
ilar findings were observed when samples were analyzed by
Blue Native-PAGE and Western blotting (Fig. 1B), where the
presence of 15-mer and 15M S.A. resulted in a reduction in the
A42 aggregation “smear” evident at the 1:5 and 1:10 ratios of
A to peptide. The LDH assay indicated that a reduction in
A42 aggregation correlated with reduced neurotoxicity, with
the parent 15-mer and 15M S.A. reducing neurotoxicity in a
dose-dependent manner and with similar potency (Fig. 1C). In
contrast, the 9-mer offered less potent neuroprotection and the
activity of the 9M S.A. peptide was again similar to the scram-
bled control peptide (Fig. 1C). The neuroprotection offered by
the candidate peptides was also confirmed using MTS assays,
which indicated increases in cell viability in line with the reduc-
tion in toxicity evident in the LDH assays.6 Together these find-
ings indicated that the 15M S.A. candidate most effectively
mimicked the activity and potency of the parent 15-mer pep-
tide. Thus, this stable analogue was further characterized
to provide insight into how it attenuates A42-induced
neurotoxicity.
15M S.A. Promoted the Formation of Non-toxic, Insoluble
Aggregates during A42 Oligomerization—The ThT and West-
ern blotting analysis described above indicated that the 15M
S.A. peptide reduced the formation of soluble A42 oligomers
(Fig. 1, A and B). However, we noticed a corresponding increase
in the formation of non-toxic, insoluble material when A42
was incubated in the presence of the 15M S.A. candidate. We
hypothesized that the reduction in soluble A42 may be con-
comitant with an increase in insoluble A42 and used denatur-
ing SDS-PAGE and Western blotting analysis to assess the rel-
ative amounts of soluble versus insoluble A42 species. As in
Fig. 1B, we found that the presence of 15M S.A. resulted in a
dose-dependent reduction in soluble A42 aggregates (Fig. 2A,
left panel), whereas the control peptide resulted in similar sol-
uble A42 aggregates as the A42 only sample (Fig. 2A, left
panel). Increasing concentrations of 15M S.A. peptide resulted
in increasing amounts of insoluble material, whereas no insol-
uble deposits were seen for the A42 only sample, or in the
presence of the control peptide. Western blotting revealed that
A42 aggregates were indeed present in the insoluble deposits,
and the dose-dependent reduction in soluble A42 aggregates
in the presence of 15M S.A. was concurrent with an increase in
insoluble A42 aggregates (Fig. 2A, right panel). The amounts
of insoluble A42 generated in the presence of the peptides
were further characterized using denaturing SDS-PAGE, fol-
lowed by Western blotting and densitometric analysis. Soluble
A42 was measured to quantify the effect as A42, which does
not remain in the soluble fraction is by definition insoluble and
measurements made from the soluble fraction have greater
6 R. K. Barr, L. Wijaya, M. Morici, and G. Verdile, unpublished observations.
TABLE 1
Stability in 10% brain homogenate and 100% serum
9M S.A. and 15M S.A. show superior resistance to proteolytic degradation. Peptides
were prepared as 1 or 4 mM solutions in PBS and diluted in 10% rat brain homoge-
nate or 100% serum, respectively. Solutions were incubated at 37 °C for different
times, and the reactions were stopped by addition of protease inhibitors. Samples
were processed as described under “Experimental Procedures,” separated by RP-
HPLC and the level of intact peptide was determined at each time point.
Stability in 10% brain












0 25.78 29.80 12.00 14.11 32.66 27.75 20.93 18.04
15 5.55 27.80 0.47 12.35 31.05 30.35 22.61 19.40
30 0.03 29.40 0 12.35 27.51 30.12 15.03 18.42
300 0.02 33.50 0 12.51 24.00 29.21 3.56 17.74
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accuracy and precision; measurements made from the insolu-
ble fraction display elevated non-sedimenting background and
variance, attributable to small amounts of residual/surface con-
tamination after supernatant removal from the pellet (where
present). As before, dose-dependent effects of the 15-mer and
15M S.A. peptides were observed, with increasing amounts
shifting A42 of the soluble fraction and into the insoluble frac-
tion. The maximal effect was seen in the presence of 15M S.A.
peptide at the 1:10 ratio, where one-fourth of A42 remained in
the soluble fraction (Fig. 2C). The amount of insoluble material
present was also assayed, and whereas, as expected, non-sedi-
menting background was observable, the amount of A42 in
this fraction increased in line with decreases seen in the soluble
fraction and the presence of observable pellets of insoluble
material (Fig. 2C).
The utility of denaturing SDS-PAGE for analysis of A
assemblies is somewhat limited, given that most protein com-
plexes and oligomers dissociate when treated with SDS, and
thus observation of monomers and low-molecular weight olig-
omers by SDS-PAGE does not reveal whether larger assemblies
existed prior to SDS addition (33). Thus, we chose to better
characterize the soluble and insoluble A assemblies formed in
the presence of 15M S.A. using AFM. We found that A42
oligomers formed in the absence of 15M S.A. were predomi-
nantly 1.5– 4 nm in diameter, with a few larger aggregates 8 –12
nm in diameter (Fig. 2B, left panel). However, A assemblies
formed in the presence of 15M S.A. ranged from smaller (2– 6
nm diameter) to extreme (25–30 nm) size (Fig. 2B, center
panel). The absence of aggregates in the presence of 15M S.A.
only (Fig. 2B, right panel) suggests that aggregation of this pep-
tide does not contribute to formation of larger A assemblies.
Taken together, it appears that the 15M S.A. peptide binds
A42, alters its oligomerization, and promotes the formation of
non-toxic amorphous aggregates.
15M S.A. Binds Pre-formed A42 Oligomers, as Shown by
Surface Plasmon Resonance/Biacore and Coimmunoprecipita-
tion Assays—The above assays indicated that 15M S.A. could
influence the formation of A42 oligomers. We next extended
these findings by demonstrating that 15M S.A. could also inter-
act with pre-formed A42 oligomers (oA42) using two com-
plementary measures of protein-protein interactions; surface
plasmon resonance/Biacore assays and coimmunoprecipita-
tion analysis. For these assays, we utilized two stable analogue
control peptides (CTL1 S.A. and CTL2 S.A., “Experimental
Procedures”), which were validated in ThT and LDH assays and
found to mimic the activity of the CTL1 peptide used in our
previous assays.6 For surface plasmon resonance assays, 15M
S.A. was immobilized on a Biacore sensorchip and oA42 con-
centrations over 5– 40 M were injected and monitored for
binding to 15M S.A. It was evident that oA42 bound 15M S.A.
in a dose-dependent manner (Fig. 3A). To confirm the specific-
ity of this interaction, we next performed solution competition
assays where free 15M S.A. peptide or control peptides were
co-injected with oA42. For these studies, we used an oA42
FIGURE 1. Effects of candidate peptides on A42 aggregation and neu-
rotoxicity. A42 was incubated under conditions favoring oligomeriza-
tion, in the presence or absence of the candidate peptides. At t  24 h,
samples were assayed for A42 aggregation as measured by ThT relative
fluorescence units (RFU) (A, mean  S.D.) and Blue Native-PAGE/Western
blotting for A42 (B). The dividing line in B indicates that data has been
spliced to simplify viewing, but all samples were from a single experiment.
C, oligomeric A42 stocks were diluted to 20 M concentration and used
to treat M17 neuroblastoma cells for 4 days. A42-induced neurotoxicity
was assessed by LDH release from the cells (mean  S.D.). All data are from
a single trial, but reflects the findings from at least 3 independent
experiments.
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FIGURE 2. 15M S.A. reduced the formation of soluble A42 oligomers and concurrently increased the formation of insoluble A42 aggregates. A42
was incubated under conditions favoring oligomerization, in the presence or absence of 15M S.A. or control peptides at the indicated molar ratios. At t  24 h,
soluble and insoluble fractions (where present) were assayed for the presence of A42 by SDS-PAGE and Western blotting (A, n  3). The asterisks indicate
samples with a reduction in soluble A42 aggregates. The dividing line indicates that data has been spliced to simplify viewing, but all samples were from a
single experiment. B, AFM of combined soluble/insoluble A42 aggregates formed in the presence or absence of the 15M S.A. peptide under conditions
favoring oligomerization (n  2). C, SDS-PAGE and Western blotting results quantifying shift from soluble to insoluble A42. A representative blot of reduced
soluble A42 is shown above the corresponding quantified results of 3 experiments, each with gels run in duplicate (mean  S.D.). Spotted bars show insoluble
A42. The “p” marker indicates samples in which a small pellet of insoluble material could be observed by careful inspection.
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concentration of 20 M, which was found to give reproducible
responses in replicate injections over multiple cycles in a given
experiment. We found that increasing concentrations of free
15M S.A. in solution resulted in a dose-dependent reduction in
oA42 binding the immobilized 15M S.A. on the sensorchip
(Fig. 3B). However, equivalent concentrations of two different
control peptides could not mimic this action and did not reduce
the amount of oA42 binding to immobilized 15M S.A. (Fig.
3B). To confirm these findings, we performed complementary
studies involving coimmunoprecipitation analysis. Here, Alexa
488-labeled oA42 was incubated with TMR-labeled 15M S.A.
peptide to promote the formation of a protein complex, which
was captured by immunoprecipitation using 6E10 antibody to
bind oA species. Denaturing SDS-PAGE was used to separate
the protein complexes and oA42 and 15M S.A. were visualized
via their respective fluorescent labels. The 15M S.A. peptide
coimmunoprecipitated with oA42 in a dose-dependent man-
ner (Fig. 3C). Furthermore, the amount of labeled, coimmuno-
precipitated 15M S.A. peptide could be reduced by competition
in solution with increasing quantities of unlabeled 15M S.A.
peptide (Fig. 3C). These findings confirmed the results of the
surface plasmon resonance assays and collectively indicate that
the 15M S.A. peptide directly interacts with oA42.
We extended the surface plasmon resonance analysis to
obtain an estimate of the affinity of the interaction between
15M S.A. and oA42, by fitting the experimental data to models
within the BiaEvaluation v4.1 software. It is crucial to highlight
that this value is only an overall estimate of binding affinity
FIGURE3.15M S.A. binds pre-formed A42 oligomers, as shown by surface plasmon resonance and coimmunoprecipitation assays.ABiacore/SPRexperiment
(sensorgrams showing blank-subtracted response (Resp. Diff) (i) and bar chart of maximal response (ii)) illustrates dose-dependent binding of A42 oligomers (oA42)
to immobilized 15M S.A. peptide on a CM5 sensorchip surface (A, single trial illustrated, n  3). Concentrations of oA42 injected were 5, 10, 15, 20, and 40 M. B,
competition assay indicating that binding between oA42 (20 M) and immobilized 15M S.A. was effectively disrupted by free 15M S.A. in solution, but not equivalent
concentrations of two control peptides (CTL1 S.A. and CTL2 S.A.) (single trial illustrated, n  2). C, coimmunoprecipitation experiment with Alexa 488-labeled oA42
captured using 6E10 antibody and detection of bound TMR-labeled 15M S.A. peptide. Immunocomplexes were separated by denaturing SDS-PAGE and fluores-
cently labeled proteins were visualized using a Typhoon imaging system. TMR-15M S.A. peptide was bound by Alexa 488-A42 in a concentration-de-
pendent manner, which could be reduced by the presence of an excess of unlabeled 15M S.A. peptide in solution (n  2).
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across the entire spectrum of oligomers present in the oA42
preparation, which is a heterogeneous mixture of aggregates.
The best fit occurred for a 1:1 binding model with drifting base-
line correction (2  0.214) and yielded a KD value of low
micromolar value (11 M), indicating a moderate affinity
between the 15M S.A. peptide and oA42, and similar to other
reports of A-peptide interactions (34).
15M S.A. Binds Monomeric, Oligomeric, and Fibrillar A42
in Biacore Assays—Thus far, we had demonstrated that 15M
S.A. could influence oligomer formation and directly bind pre-
formed oA42. We further investigated the ability of this pep-
tide to bind less aggregated A preparations (monomeric (m)
A42) and more aggregated preparations (fibrillar (f) A42).
To allow a comparison of 15M S.A. binding to different A
species, a sensorchip was generated with immobilized mono-
meric, oligomeric, and fibrillar A42 preparations as described
under “Experimental Procedures.” A series of 15M S.A. concen-
trations were injected across the surfaces, monitored for bind-
ing to the respective A42 species, and the data were corrected
for the relative amount of immobilized material on the individ-
ual flow cells. We found that 15M S.A. interacted with all of the
A42 species in a concentration-dependent manner, but the
highest magnitude of binding was seen for the A42 fibrils (Fig.
4). This most likely reflects the fact that the A42 fibrils have
multiple binding sites for 15M S.A., given that they are com-
posed of repeating units of monomeric A42. Overall, this data
shows that the 15M S.A. peptide is able to bind unaggregated,
monomeric A42 (perhaps accounting for its earlier effects
(Fig. 1) in reducing the formation of oA42) as well as oligo-
meric and fibrillar A42 assemblies. The binding of 15M S.A. to
more mature amyloid species was investigated further below.
15M S.A. Can Detect Amyloid Plaques in ex Vivo Immunohis-
tochemical Staining of AD Brain Slices—Given the ability of
15M S.A. to interact with A42 fibrils, we extended this finding
to investigate whether TMR-labeled 15M S.A. could be used to
stain amyloid plaques ex vivo using brain tissue sections from
AD model mice, in comparison with thioflavin S, which binds
mature amyloid deposits and readily detects these plaques. In
ex vivo staining of brain tissue from 8-month-old 5xFAD AD
model mice, thioflavin S staining revealed extensive plaques
within the brain (Fig. 5A). In comparison, serial sections treated
with the TMR-labeled 15M S.A. peptide also resulted in stain-
ing of some amyloid deposits, but to a lesser extent than thio-
FIGURE 4. 15M S.A. binds monomeric, oligomeric, and fibrillar A42.
A42 was incubated under conditions favoring formation of monomers
(mA42), oligomers (oA42), or fibrils (fA42) as described under “Experi-
mental Procedures.” These were immobilized on individual flow cells of a CM5
sensorchip, where an unmodified surface was reserved for blank-subtraction.
A series of concentrations of 15M S.A. peptide were injected across these
surfaces and monitored for binding. In each case, the binding response was
corrected for the relative quantity of immobilized material (RU bound/RU
immobilized). 15M S.A. bound all of the immobilized A42 assemblies, with
the highest binding response observed for A42 fibrils.
FIGURE 5. 15M S.A. binds amyloid deposits in brain tissue from the 5xFAD mouse model of AD. Ex vivo staining of serial sagittal sections from the
subiculum of 8-month-old AD model mice (5xFAD) or age-matched non-transgenic controls (Non-Tg) (10 mM thickness, 10 magnification, scale bar  200
mm; inset  40 magnification) is shown. A, amyloid deposits as detected by thioflavin S staining. B, TMR-labeled 15M S.A. peptide bound a subset of the total
amyloid deposits. C, TMR-labeled 15M S.A. peptide did not stain equivalent brain tissue from Non-Tg control mice. D, TMR-labeled control peptide (CTL2 S.A.)
did not result in any detectable staining of amyloid deposits in 5xFAD brain tissue (n  2).
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flavin S (Fig. 5B). Notably, the TMR-labeled 15M S.A. peptide
did not stain control (non-AD) brain tissue from age-matched
control mice in related experiments (Fig. 5C). Additionally, a
TMR-labeled control peptide did not result in any comparable
staining of amyloid deposits in the 5xFAD brain tissue (Fig. 5D).
These findings were replicated in brain tissue from another
transgenic AD mouse model, the TgCRND8 (Fig. 6). The TMR-
labeled 15M S.A. peptide (Fig. 6B), but not the control (CTL2
S.A., Fig. 6D) peptide, stained amyloid deposits in TgCRND8
brain tissue but not in tissue from non-transgenic littermates
(Fig. 6A). These data in brain tissue from two independent AD
mouse models indicate that, in addition to binding A42 mono-
mers, oligomers, and fibrils in vitro, 15M S.A. was also capable
of binding mature amyloid deposits in brain tissue ex vivo.
Tritiated 15M S.A. Peptide Is Detected in the Brains of Mice
following Intravenous Administration—The demonstration of
binding of the 15M S.A. peptide to aggregated A42 in vitro and
ex vivo suggested it may also have the potential to bind A42 in
vivo. However, the blood-brain barrier (BBB) represents a
major hurdle for the delivery of molecules into the brain from
the periphery. To make a preliminary assessment of the ability
of the 15M S.A peptide to cross the BBB in vivo, 10 Ci of
tritiated peptide was administered by intravenous injection to
mice as described under “Experimental Procedures,” and its
concentration in brain and plasma was determined in samples
collected over a 0.5– 4 h period. Scintillation counting revealed
that the plasma concentrations of tritiated peptide decreased
with time, as expected following intravenous administration.
However, the tritiated peptide was detected in brain homoge-
nate at the initial t  30 min time point and remained relatively
constant until t  4 h, suggesting that the peptide remains sta-
ble in the brain (Fig. 7A). We further performed control exper-
iments to ensure that the measured radioactivity in brain and
plasma samples corresponded to intact 3H-15M S.A. peptide,
rather than free label or degradation products (Fig. 7, B and C).
There was no apparent shift in the retention time of 3H-labeled
15M S.A. in brain and plasma samples collected at designated
time points, suggesting that the majority of detected radioac-
tivity was associated with intact peptide. This provided initial
evidence that the 15M S.A. peptide can cross the blood-brain
barrier in vivo following intravenous administration and poten-
tially access brain-based A42 targets.
Discussion
Here, we extend our earlier findings (1) and report the gen-
eration of a 15-mer stable analogue peptide that targets A42.
We provide evidence that the peptide is multifaceted in its
actions, in that it can bind monomeric, oligomeric, and fibrillar
A42 and also reduce the formation of neurotoxic A42
oligomers.
The ability of the 15M S.A. peptide to interfere with forma-
tion of oligomers is of particular interest, given their likely role
in mediating the neurotoxicity of A42. We noted that in the
presence of 15M S.A., the formation of soluble A42 oligomers
was decreased, with a concurrent increase in the formation of
non-toxic, amorphous aggregates. Thus, it appears that the
15M S.A. peptide can shift the equilibrium between different
A42 assemblies and favor the formation of non-toxic, amor-
phous aggregates rather than soluble oligomers. A recent
report demonstrated that the aggregation of A42 is promoted
by a positive feedback loop that originates from the interactions
between the monomeric and fibrillar forms of this peptide (35).
More specifically, once a small but critical concentration of
amyloid fibrils has accumulated, the toxic oligomeric species
are predominantly formed from monomeric peptide molecules
through a fibril-catalyzed secondary nucleation reaction (35).
FIGURE 6. 15M S.A. binds amyloid deposits in brain tissue from the TgCRND8 mouse model of AD. Ex vivo staining of serial coronal sections from the whole
brain of 8-month-old AD model mice (TgCRND8) or age-matched non-transgenic controls (Non-Tg) (10-m thickness, 5 magnification, scale bar  200 m;
inset  10 magnification) is shown. DAPI was used as a nuclear counterstain. A, TMR-labeled 15M S.A. peptide did not stain cortical brain tissue from Non-Tg
control mice. B, TMR-labeled 15M S.A. peptide bound to amyloid deposits in TgCRND8 cortical brain tissue. C and D, TMR-labeled control peptide (CTL2 S.A.) did
not result in any detectable staining of amyloid deposits in Non-Tg or TgCRND8 brain tissue (n  1).
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Given our data showing that 15M S.A. binds monomers and
fibrils, it is feasible that it could interfere with such a nucleation
reaction. Further validation is required to determine whether
15M S.A. can inhibit the formation of soluble A42 oligomers
via interactions with monomers, fibrils, or a combination of
these A42 moieties.
The ability of 15M S.A. to bind preformed A42 oligomers is
also highly significant, particularly with respect to developing
agents that target early events in the disease process. As men-
tioned earlier, the formation of soluble aggregates is thought to
occur prior to plaque and tangle formation and promote the
neurodegenerative process. Current evidence suggests that A
deposition may precede mild cognitive impairment (the first
clinical manifestation of AD) by 10 –20 years (36 –38) and so
the accumulation of A oligomers could occur more than 20
years prior to the development of a clinical AD phenotype. It
would be advantageous to have the ability to image some of the
earliest events in the development of AD, when therapeutic
approaches to neutralize and/or clear neurotoxic oligomers
might prevent the resulting neuronal injury and cognitive
decline. Given the multifaceted action of 15M S.A. in inhibiting
oligomer formation and binding preformed oligomers, it may
prove useful in both diagnostic and therapeutic approaches tar-
geting preclinical AD.
Peptide-based drugs offer several advantages compared with
other popular alternatives, including antibodies. Their small
size means they can be produced at a lower cost, with higher
activity per mass and often less immunogenicity (39). A further
hurdle for antibody-based approaches is penetration of the
BBB, which allows only 0.1% of peripheral antibody to gain
access to the central nervous system (40) and thus smaller
peptides may be more amenable to BBB transport. Certainly,
our preliminary data presented here suggests that the 15M
S.A. peptide is capable of crossing the BBB in vivo to some
degree (Fig. 7). Furthermore, a recent study designed short
20-mer peptides to bind the C terminus of APP-C99 and
following intraperitoneal injection of mice showed efficacy
at reducing cerebral A levels (41), providing initial evidence
for the potential of similar sized peptides to cross the BBB. In
our ongoing studies, we are further investigating the extent
of BBB transport of 15M S.A. and its ability to bind A42
aggregates in vivo, to better define its diagnostic and thera-
peutic capabilities.
Several peptide-based agents have been designed to target
A and inhibit its aggregation. Many of these peptides can
reduce A aggregation and neurotoxicity in vitro and modified
versions with improved stability have further been shown to be
effective in vivo (e.g. Ref. 26 and 42– 49). Other peptides that
have recently been reported to target oligomeric A in partic-
ular include a peptide based on the N-terminal fragment of the
cellular prion protein (N1) that blocked the formation of amy-
loid fibrils in vitro and bound A42 oligomers and inhibited
their neurotoxicity in vivo (50) and the ABP-p-4 –5 synthetic
peptide corresponding to a region of the human pericentriolar
material 1 protein that preferentially bound A42 oligomers
and protected against their neurotoxicity in vitro (51). Few of
FIGURE 7. Tritiated 15M S.A. peptide is detected in the brains of mice following intravenous administration. Male Swiss Outbred mice were administered
10 Ci of 3H-labeled 15M S.A. peptide by tail vein injection. Brain and plasma samples were collected over a 0.5– 4-h period and the determination of
compound in plasma and brain homogenate was performed by liquid scintillation counting (A, n  3). Data are mean  S.E. B and C, assessment of the
intactness of 3H-15M S.A. peptide in samples from brain (B) and plasma (C), respectively. HPLC/scintillation counting indicated a similar retention time for
radioactivity detected in brain/plasma samples, and undegraded 3H-labeled 15M S.A. peptide (Control), suggesting that the majority of detected radioactivity
in samples was due to intact peptide.
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these agents have progressed to the clinic, often as a result of
undesirable effects (insolubility, toxicity) at the relatively high
doses required to observe their protective effects. However, it is
feasible that this may be circumvented by chemical modifica-
tions such as conjugation with polyethylene glycol, which can
improve solubility, increase circulatory half-life, reduce immu-
nogenicity, and improve delivery (52–54). Targeted delivery
methods may also improve the efficacy of peptide agents to
cross the BBB, such as “Trojan horse” approaches (55) and lipo-
somal nanoparticles (56). Another approach to enhance BBB
transport is to periodically and reversibly modulate tight junc-
tions. This has recently been demonstrated through the use of
siRNA directed against claudin-5 (57).
Although dose limitations have tended to preclude the use of
peptides as therapeutic and preventative agents thus far, their
high specificity in binding to the A42 target may render them
useful as diagnostic AD imaging probes, where only tracer
quantities are required. The ability of fluorescently tagged 15M
S.A. to bind fibrillar A42 in vitro, and amyloid plaques ex vivo,
highlights its potential as an AD imaging agent. However,
detection of mature amyloid plaques can already be achieved by
positron emission tomography imaging with current amyloid
imaging agents such as the “gold-standard” Pittsburg com-
pound B (58) (a radiolabeled analogue of ThT) and newer 18F
analogues (e.g. Refs. 59 and 60). It is important to highlight here
that the existing amyloid imaging tracers are unable to detect
oligomeric A42. Although oligomer-specific antibodies have
been identified (61, 62), antibody-based positron emission
tomography imaging has not proved useful due to poor brain
penetration of the probes (63). Here, we have used several bio-
chemical assays to indicate that the 15M S.A. peptide can
indeed bind oligomeric A42. Thus, it seems feasible that when
conjugated to an appropriate radioisotopic tracer (e.g. 18F),
15M S.A. has the potential to bridge an important gap in the
existing diagnostic techniques and non-invasively highlight the
presence of oligomeric A42 in vivo.
In our ongoing studies, we are attempting to clarify the bind-
ing sites on the 15M S.A. and A42 peptides that mediate their
interaction. This may clarify how 15M S.A. binds mono-
meric and aggregated A42 and reduces the formation of
toxic A42 oligomers in vitro, as reported here. It may fur-
ther indicate other mechanisms by which 15M S.A. might be
neuroprotective with respect to A42-induced toxicity in
vivo. For example, specific domains of A have been
reported to facilitate aggregation on and association with
lipid bilayers, with implications for bilayer stability and cell
viability (64). Thus, if 15M S.A. can make contact with such
A42 domains and interrupt lipid binding, this could poten-
tially result in neuroprotection. Finally, clarification of the
binding interface between 15M S.A. and A42 may assist in
the design of novel peptidomimetics that mimic the action of
15M S.A. and better satisfy the physicochemical require-
ments associated with in vivo therapeutics.
Overall, we have validated and characterized the binding
profile of a novel A binding peptide that has the potential to
bridge an important gap in the existing diagnostic techniques
and permit timely intervention to reduce or prevent the neuro-
degeneration and cognitive decline associated with the accu-
mulation of oligomeric A42.
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